Document Detail


Saphenous vein thrombophlebitis (SVT): a deceptively benign disease.
MedLine Citation:
PMID:  9576081     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: The association between deep vein thrombosis (DVT) and the hypercoagulable state is a well-established entity. However, the association between saphenous vein thrombophlebitis and coagulation abnormalities has not been investigated. Although thrombosis of varicose veins typically runs a benign course, phlebitis of the saphenous system may propagate to the deep system or saphenofemoral junction that requires more aggressive therapy. Given the potential similarity in clinical outcome between saphenous vein thrombophlebitis (SVT) and DVT, we have investigated the coagulation profile of patients presenting with isolated SVT.
METHODS: Seventeen consecutive patients who presented to our vascular laboratory with isolated SVT had a coagulation profile performed that included antithrombin III (AT III), protein C (PC), protein S (PS) antigen and activity levels, activated protein C (APC) resistance, factor V DNA mutation, and coagulation factors II and X. All patients had duplex scans performed on both the superficial and deep venous systems. Patients with SVT only were treated with nonsteroidal antiinflammatory drugs (NSAIDs) and warm soaks as outpatients, whereas those patients found to have DVT or a clot at the saphenofemoral junction were fully anticoagulated with heparin and coumadin therapy. All 17 patients had at least one repeat coagulation profile performed up to 5 months after their SVT occurrence to ensure that the results of hypercoagulability were not transient.
RESULTS: Ten (59%) of the 17 patients with SVT had abnormal coagulation profiles on initial presentation. All 10 patients who were hypercoagulable had repeat tests and 6 (35%) remained abnormal. Four patients who had abnormal results converted to normal values. Seven patients with normal coagulation profiles on initial presentation had repeat tests and all remained normal.
CONCLUSION: The incidence of the hypercoagulable state in patients with SVT is high. Thirty-five percent of patients with isolated SVT had consistently abnormal coagulation profiles. Patients with SVT may be prone to the development of DVT or saphenofemoral junction thrombophlebitis and should be closely followed after the initial diagnosis of hypercoagulability.
Authors:
J N Hanson; E Ascher; P DePippo; E Lorensen; M Scheinman; W Yorkovich; A Hingorani
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of vascular surgery     Volume:  27     ISSN:  0741-5214     ISO Abbreviation:  J. Vasc. Surg.     Publication Date:  1998 Apr 
Date Detail:
Created Date:  1998-05-28     Completed Date:  1998-05-28     Revised Date:  2012-10-03    
Medline Journal Info:
Nlm Unique ID:  8407742     Medline TA:  J Vasc Surg     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  677-80     Citation Subset:  IM    
Affiliation:
Maimonides Medical Center, Brooklyn, NY 11219, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Ambulatory Care
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
Anticoagulants / blood,  therapeutic use
Antigens / blood
Antithrombin III / analysis
Blood Coagulation Disorders / blood,  complications,  physiopathology
DNA / genetics
Factor V / analysis,  genetics
Factor X / analysis
Female
Femoral Vein / physiopathology
Fibrinolytic Agents / blood
Follow-Up Studies
Heparin / therapeutic use
Humans
Incidence
Male
Middle Aged
Mutation / genetics
Phlebitis / physiopathology
Postphlebitic Syndrome / etiology,  physiopathology
Protein C / analysis
Protein S / analysis,  immunology
Prothrombin / analysis
Saphenous Vein / physiopathology*,  ultrasonography
Serine Proteinase Inhibitors / blood
Thrombophlebitis / etiology
Thrombosis / blood,  etiology,  physiopathology*,  therapy,  ultrasonography
Treatment Outcome
Ultrasonography, Doppler, Duplex
Varicose Veins / physiopathology
Warfarin / therapeutic use
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Anticoagulants; 0/Antigens; 0/Fibrinolytic Agents; 0/Protein C; 0/Protein S; 0/Serine Proteinase Inhibitors; 81-81-2/Warfarin; 9000-94-6/Antithrombin III; 9001-24-5/Factor V; 9001-26-7/Prothrombin; 9001-29-0/Factor X; 9005-49-6/Heparin; 9007-49-2/DNA

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Foot venous pressure measurement for evaluation of lower limb venous insufficiency.
Next Document:  In vitro evaluation of multiple arterial stenoses using three-dimensional power Doppler angiography.